AbClon Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 67

Employees

  • Stock Symbol
  • 174900

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $17.49
  • (As of Friday Closing)

AbClon General Information

Description

Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO.

Contact Information

Website
www.abclon.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Number 1401
  • 285, Digital-ro, Guro-gu
  • Seoul, 08381
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • Number 1401
  • 285, Digital-ro, Guro-gu
  • Seoul, 08381
  • South Korea
+82

AbClon Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbClon Stock Performance

As of 20-Nov-2026, AbClon’s stock price is $17.49. Its current market cap is $349M with 20M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.49 $18.28 $11.17 - $63.72 $349M 20M 182K -$0.62

AbClon Financials Summary

As of 30-Jun-2026, AbClon has a trailing 12-month revenue of $3.66M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 337,184 561,560 167,879 174,735
Revenue 3,657 3,312 1,715 2,200
EBITDA (11,803) (11,806) (10,386) (8,198)
Net Income (12,005) (12,583) (11,947) (9,870)
Total Assets 41,802 49,129 32,711 35,258
Total Debt 4,821 4,920 11,712 9,778
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AbClon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AbClon‘s full profile, request access.

Request a free trial

AbClon Patents

AbClon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4713367-A1 Anti-cd30 antibody and chimeric antigen receptor comprising thereof Pending 18-May-2023
US-12668640-B2 Anti-cd30 antibody and chimeric antigen receptor comprising thereof Active 18-May-2023
US-20240392023-A1 Anti-cd30 antibody and chimeric antigen receptor comprising thereof Active 18-May-2023
WO-2024237521-A1 Anti-cd30 antibody and chimeric antigen receptor comprising thereof Inactive 18-May-2023
JP-2026518729-A Anti-cd30 antibody and chimeric antigen receptor containing the same Pending 18-May-2023 C07K16/2878
To view AbClon’s complete patent history, request access »

AbClon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbClon Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AbClon‘s full profile, request access.

Request a free trial

AbClon Investments (2)

AbClon’s most recent deal was a Corporate Asset Purchase with Shingwang (4,276 Square Meter Facility Site in Siheung, South Korea) for . The deal was made on 27-Aug-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Shingwang (4,276 Square Meter Facility Site in Siheung, South Korea) 27-Aug-2019 Corporate Asset Purchase Buildings and Property
ComArtSystems (Land and Building Property in Seoul, South Korea) 19-Feb-2018 Corporate Asset Purchase Buildings and Property
To view AbClon’s complete investments history, request access »

AbClon ESG

Risk Overview

Risk Rating

Updated December, 31, 2023

32.53 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Biotechnology

Subindustry

of 394

Rank

Percentile

To view AbClon’s complete esg history, request access »

AbClon FAQs

  • When was AbClon founded?

    AbClon was founded in 2010.

  • Where is AbClon headquartered?

    AbClon is headquartered in Seoul, South Korea.

  • What is the size of AbClon?

    AbClon has 67 total employees.

  • What industry is AbClon in?

    AbClon’s primary industry is Drug Discovery.

  • Is AbClon a private or public company?

    AbClon is a Public company.

  • What is AbClon’s stock symbol?

    The ticker symbol for AbClon is 174900.

  • What is the current stock price of AbClon?

    As of 20-Nov-2026 the stock price of AbClon is $17.49.

  • What is the current market cap of AbClon?

    The current market capitalization of AbClon is $349M.

  • What is AbClon’s current revenue?

    The trailing twelve month revenue for AbClon is $3.66M.

  • What is AbClon’s annual earnings per share (EPS)?

    AbClon’s EPS for 12 months was -$0.62.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process